Effects of aqueous leaves extract of Aloe barbadensis on blood glucose levels of streptozocin-induced diabetic Wistar rats

Abstract

The study was to investigate the antidiabetic of aqueous extract of leaves of plant Aloe barbadensis.  In STZ induced diabetes in rats, a study was conducted on six groups of six male Wister rats each to evaluate the hypoglycaemic effect. Diabetes was induced in rodents by intravenous (i.v) infusion of STZ at a portion of 50 mg/kg body weight, disintegrated in 00.10M virus citrate cushion (pH = 04.50). Blood glucose level was estimated utilizing GOD-POD (Kit spin react). Blood tests were pulled back from the retro-orbital plexus under light ether. A. barbadensis (ALEC) was exposed to hostile to diabetic action in rodents where STZ was utilized as a portion of 120 mg/kg in intraperitoneal portion as a diabetogenic specialist to an acquainted diabetic with test rodents. In intense streptozotocin prompted models fasting blood glucose level was recorded on multi-day as basal worth 4^th, 7^th and 10^th day. Aqueous extracts of leaves of A. barbadensis at portion 250 and 500 mg/kg showed portion subordinate critical enemy of hyperglycemic action on 4^th, 7^th and 10^th day post-treatment. ALEC portion of 100 mg/kg likewise caused a decrease in blood glucose level; however, outcomes were found factually non-noteworthy. The Antihyperglycemic impact of fluid leaves concentrate of A. barbadensis at portion 100 mg/kg was discovered less viable than reference standard medications glibenclamide. The most extreme decrease was seen on the 10^th day of the greatest portion of 500 mg/kg ALEC. Glibenclamide produces a critical decrease in blood glucose level in contrast with diabetic control. Glibenclamide was used as a standard drug, and the results were compared in reference to it. The study confirmed the aqueous extract of Aloe barbadensis has significant and sustained oral hypoglycaemic activity, comparable with the hypoglycaemic effect of glibenclamide, a sulfonylurea derivative.